Testicular embryonal carcinoma

Summary

Testicular embryonal carcinoma (MONDO:0006446) is a cancer and 4 clinical trials. Top therapeutic interventions include bleomycin sulfate and cisplatin. A subtype of testicular pure germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	testicular embryonal carcinoma
Mondo ID	MONDO:0006446
EFO	EFO:1000565
DOID	DOID:5680
NCIT	C6341
UMLS	C0238448
MedGen	66771
GARD	0024413
Anatomy (UBERON)	UBERON:0000473
Is cancer (heuristic)	yes

Also known as: embryonal carcinoma of testis · embryonal carcinoma of the testis · embryonal testis carcinoma · testicular embryonal carcinoma · testis embryonal carcinoma

Data availability: 23 cell lines.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › gonadal germ cell tumor › testicular germ cell tumor › testicular pure germ cell tumor › testicular embryonal carcinoma

Related subtypes (3): testicular trophoblastic tumor, testicular yolk sac tumor, testicular seminoma

Subtypes (2): childhood embryonal testis carcinoma, intratubular embryonal carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00053352	PHASE3	COMPLETED	Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
NCT00467051	PHASE2	COMPLETED	Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
NCT00060372	PHASE1	COMPLETED	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
NCT01434355	Not specified	COMPLETED	DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN SULFATE	4	1
CISPLATIN	4	1